Free tool
FAERS Monitor: Sarclisa Escena
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761445 or its brand name (Sarclisa Escena, Isatuximab-Irfc). Reports on generic versions are filed under their own applications.
Reports
54
Serious
47
87% of reports
Hospitalization
31
Death reported
6
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- neutropenia9
- urinary tract infection6
- neutrophil count decreased5
- upper respiratory tract infection4
- abdominal pain3
- drug hypersensitivity3
- headache3
- infusion related reaction3
- malaise3
- off label use3
- platelet count decreased3
- pneumonia3
- anaemia2
- anaphylactic reaction2
- cellulitis2
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2021 | 2 |
| 2022 | 4 |
| 2023 | 11 |
| 2024 | 17 |
| 2025 | 11 |
| 2026 | 9 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,105 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| neutrophil count decreasedSignal | 5 | 47.8 | 20.7 | 185 |
| upper respiratory tract infectionSignal | 4 | 33.7 | 13.1 | 97 |
| neutropeniaSignal | 9 | 25.8 | 14.2 | 192 |
| infusion related reactionSignal | 3 | 17.6 | 5.9 | 32 |
| cellulitis | 2 | 15.5 | 4.0 | 15 |
| anaphylactic reaction | 2 | 14.1 | 3.6 | 13 |
| urinary tract infectionSignal | 6 | 13.7 | 6.4 | 59 |
| platelet count decreasedSignal | 3 | 11.0 | 3.7 | 18 |
| drug hypersensitivitySignal | 3 | 6.0 | 2.0 | 8 |
| abdominal painSignal | 3 | 5.0 | 1.7 | 6 |
| anaemia | 2 | 4.1 | 1.0 | 2 |
| pneumonia | 3 | 3.6 | 1.2 | 3 |
| malaise | 3 | 2.7 | 0.9 | 2 |
| headache | 3 | 1.9 | 0.6 | 1 |
| off label use | 3 | 1.3 | 0.4 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.